The number of kidney transplants performed worldwide is increasing year by year, exceeding 95,000 in the latest statistics from 2019. Today there are more than 1 million kidney transplant patients in the world, however, 50% of them reject the transplanted organ by 10 years.
These patients require long term treatment with different immunosuppressive drugs and doses to limit the risk of graft rejection due to immune-mediated kidney injury.
Immunosuppressive therapy is the basis of the patient’s clinical evolution. Considering the level of resistance and sensitivity to each drug, personalised treatment is essential in the management of the patient’s response.
Along these lines, the IMMUNOBIOGRAM®, an IVD that allows the doctor to know the sensitivity level of immunosuppressant drugs, helps to optimize and personalize the immunosuppressive treatment for each patient.
How does it work?
- A blood sample is taken from the transplant patient for the processing of the immune system cells.
- The response of the cells to each immunosuppressant is measured in order to obtain levels of resistance or sensitivity to each drug.
- The doctor receives a report of the results along with an interpretation guide.
What are the potential benefits?
- Improves the patient’s quality of life
- Helps the doctor to prescribe a personalised immunosuppressive treatment
- Costs savings for the healthcare system.
This message is exclusively intended for health professionals